LONDON, UK / ACCESSWIRE / December 10, 2019 / With the US Phase IIb study results now expected around mid-2020, we have examined the study design and our expectations for the results. Separately, we have looked beyond the current study and indication to the application of Destiny Pharma's products in infections associated with biofilms. Our valuation is £70.2m, or 160p per share.
We value Destiny at £70.2m, or 160p per share, reduced from £83.2m or 191p per share. This is driven by reduced pricing assumptions ($400 per XF-83 course in the US from $450), and a delay in our expected US launch (2023 from 2022), based on company guidance. However, this is still well above current market valuations, which imply pricing and probabilities of success well below historical standards.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Nathaniel Calloway, +1 646 653 7036
Maxim Jacobs, +1 646 653 7027
[email protected]
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited